

## How can your healthcare system support a wider access to Value Added Medicines?

Recognise the additional benefit of value added medicines and ensure differentiation with standard of care in the decision-making process

Ensure that the decision-making process considers relevant value dimensions that demonstrate the benefits of value added medicines in the different purchasing/procurement mechanisms

Provide a balanced assessment of the benefits of value added medicines with pragmatic evidence that demonstrates the benefits of value added medicines

Taking into consideration the voice of patients, healthcare professionals and remaining actors in the healthcare community

### ENVIRONMENT OF VALUE ADDED MEDICINES IN EUROPE

 IQVIA™ Report



Belgium recognises the importance of Value Added Medicines to patients, healthcare professionals and healthcare systems. Since 2018, Belgium has been leading in recognising the benefits of value added medicines in their P&R process!

- ✓ **Now separated (class 3c) from other generics medicines (class 3a and 3b) provided that:**
  - There is no other medicine with the same characteristics
  - The value-added benefit of the medicine (compared to "standard" generic) is justified by means of pragmatic scientific argumentation.

Click on the map to know more about the value added medicines' environment per country!